P+P advises 415 CAPITAL on launch of new MedTech Venture Capital Fund

Munich-based Venture Capital firm 415 CAPITAL has successfully held the first closing of its new MedTech Venture Capital fund (415 CAPITAL Fund I). The fund is aiming for a final closing at up to EUR 85 million later in 2020.

The fund will invest in medical device companies in Europe, Israel and the United States with a strong focus on startups developing groundbreaking technologies to diagnose and treat Cardiovascular disease and its associated risk factors, including coronary artery disease, structural heart disease, stroke, hypertension and vascular disease. Cardiovascular disease is the worldwide leading cause of death and the single largest cost driver in the global Healthcare system.

415 CAPITAL has been formed by MedTech entrepreneurs and investors Frank Groenewegen, David Thompson and Frederik Groenewegen. The three founding partners share a 28-year history of introducing medical device technologies to the European market and making personal investments in innovative MedTech companies. The team has privately funded 45 MedTech startups over the years.

The first closing investor base includes the European Investment Fund (EIF), KfW Capital, as well as several reputable family offices and distinguished MedTech entrepreneurs.

P+P Pöllath + Partners advised 415 CAPITAL on all contractual, tax and regulatory aspects of the fund structuring, marketing and investor negotiations with the following Berlin-based private funds team:

• Dr. Philip Schwarz van Berk (Partner, Private Funds)
• Dr. Philip Mostertz (Senior Associate, Private Funds)